环丁基甲氨盐酸盐 | 5454-82-0

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 环丁基甲氨盐酸盐
• 中文别名: 环丁基甲胺盐酸盐
• 英文名称: cyclobutylmethylamine hydrochloride
• 英文别名: cyclobutylmethanamine hydrochloride；1-cyclobutylmethanamine hydrochloride；C-cyclobutylmethylamine hydrochloride；Cyclobutylmethanamine;hydron;chloride；cyclobutylmethanamine;hydron;chloride
• CAS: 5454-82-0
• 化学式: C₅H₁₁N*ClH
• mdl: MFCD00034952
• 分子量: 121.61
• InChiKey: JVZOVVGVPJVLSL-UHFFFAOYSA-N

物化性质

• 熔点：
  >212°C (dec.)
• 溶解度：
  DMSO（少许）、甲醇（少许）、水（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2921300090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Cyclobutylmethylamine, HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Cyclobutylmethylamine, HCl
CAS number: 5454-82-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H11N.ClH
Molecular weight: 121.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  环丁基甲氨盐酸盐 在 sodium azide 、 copper(ll) sulfate pentahydrate 、 三氟甲磺酸 、 sodium carbonate 、 sodium ascorbate 、 三乙胺 、 L-脯氨酸 作用下， 以 甲醇 、 水 、 叔丁醇 为溶剂， 反应 29.0h， 生成 (1S,2R,3S,4R,5S)-4-(2-azido-6-((cyclobutylmethyl)amino)-9H-purin-9-yl)-2,3-dihydroxy-Nmethylbicyclo[3.1.0]hexane-1-carboxamide
  参考文献：
  名称：

  Rigidified A₃ Adenosine Receptor Agonists: 1-Deazaadenine Modification Maintains High in Vivo Efficacy

  摘要：

  Substitution of rigidified A(3) adenosine receptor (AR) agonists with a 2-((5-chlorothiophen-2-y1)ethynyl) or a 2-(4-(5-chlorothiophen-2-y1)-1H-1,2,3-triazol-1-yl)) group provides prolonged protection in a model of chronic neuropathic pain. These agonists contain a bicyclo[3.1.0]hexane ((N)-methanocarba) ring system in place of ribose, which adopts a receptor-preferred conformation. N-6-Small alkyl derivatives were newly optimized for A(3)AR affinity and the effects of a 1-deaza-adenine modification probed. 1-Deaza-N-6-ethyl alkyne 20 (MRS7144, K-i 1.7 nM) and 1-aza N-6-propyl alkyne 12 (MRS7154, K-i 1.1 nM) were highly efficacious in vivo. Thus, the presence of N1 is not required for nanomolar binding affinity or potent, long-lasting functional activity. Docking of 1-deaza compounds to a receptor homology model confirmed a similar binding mode as previously reported 1-aza derivatives. This is the first demonstration in nonribose adenosine analogues that the 1-deaza modification can maintain high A(3)AR affinity, selectivity, and efficacy.

  DOI：

  10.1021/acsmedchemlett.5b00150
• 作为产物：
  描述：

  环丁腈 在 硼烷四氢呋喃络合物 、 盐酸 作用下， 以 甲醇 为溶剂， 反应 2.5h， 以86%的产率得到环丁基甲氨盐酸盐
  参考文献：
  名称：

  NOVEL COMPOUNDS

  摘要：

  本发明提供了化合物的公式（I）及其药用盐，其中R1、X、m、R2、Y、R3、Z、n、R4、A和B的定义如规范中所述，以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的应用。

  公开号：

  US20150057298A1

文献信息

• [EN] THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE<br/>[FR] DÉRIVÉS DE THIOPHÈNE POUR LE TRAITEMENT DE TROUBLES PROVOQUÉS PAR IGE
  申请人：UCB BIOPHARMA SRL

  公开号：WO2019243550A1

  公开（公告）日：2019-12-26

  Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.

  提供了公式（I）的噻吩衍生物及其药用可接受的盐。这些化合物对于治疗或预防由IgE引起的疾病具有用途，如过敏、1型超敏反应或家族性鼻窦炎。
• [EN] BENZIMIDAZOLE ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX À BASE DE BENZIMIDAZOLE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011097491A1

  公开（公告）日：2011-08-11

  Provided are compounds of Formula (I) and (II) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

  提供的是公式(I)和(II)的化合物以及它们的药用可接受盐，它们的药物组合物，它们的制备方法，以及它们用于治疗由黄病毒科病毒家族成员如丙型肝炎病毒（HCV）介导的病毒感染。
• [EN] SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES<br/>[FR] DÉRIVÉS DE SULFONYLPIPÉRAZINE QUI INTERAGISSENT AVEC LA PROTÉINE RÉGULATRICE DE LA GLUCOKINASE POUR LE TRAITEMENT DU DIABÈTE
  申请人：AMGEN INC

  公开号：WO2012027261A1

  公开（公告）日：2012-03-01

  The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

  本发明涉及与葡萄糖激酶调节蛋白相互作用的化合物I式，或其药用盐，此外，本发明涉及使用这些化合物或其药用盐治疗2型糖尿病和其他涉及葡萄糖激酶调节蛋白的疾病和/或症状的方法，以及含有这些化合物或其药用盐的药物组合物。
• PHARMACEUTICAL COMPOSITION AND THE USE THEREOF, AND APPLICATION REGIME OF SAID PHARMACEUTICAL COMPOSITION FOR ON-DEMAND CONTRACEPTION
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160089364A1

  公开（公告）日：2016-03-31

  The invention relates to a pharmaceutical composition for non-hormonal, on-demand contraception and to processes for preparing this pharmaceutical composition. The latter comprises 2H-indazole as novel EP2 receptor antagonists in combination with COX inhibitors. The invention furthermore provides a method for non-hormonal female-controlled on-demand contraception where a pharmaceutical composition comprising EP2 receptor antagonists in combination with COX inhibitors is taken on demand prior to expected sexual intercourse.

  这项发明涉及一种用于非激素、按需避孕的药物组合物，以及制备该药物组合物的方法。后者包括2H-吲哚唑作为新型EP2受体拮抗剂，与COX抑制剂结合使用。该发明还提供了一种非激素女性控制的按需避孕方法，其中在预期性交前按需服用含有EP2受体拮抗剂与COX抑制剂的药物组合物。
• [EN] COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE<br/>[FR] COMBINAISON DE MODULATEURS DU CB2 ET D'INHIBITEURS DE LA PDE4 UTILISEE EN MEDECINE
  申请人：GLAXO GROUP LTD

  公开号：WO2005074939A1

  公开（公告）日：2005-08-18

  Combination of one or more CB2 modulators such as a compound of formula (I), (II) and (III); and one more PDE4 inhibitors are useful of treating conditions which are mediated by the activity of CB2 receptors or conditions which are mediated by PDE4, such as an immune disorder, an inflamatory disorder, pain, rheumatoid.

  一种或多种CB2调节剂的组合，例如式(I)、(II)和(III)的化合物；以及一种或多种PDE4抑制剂对于治疗由CB2受体活性介导的疾病或由PDE4介导的疾病，如免疫紊乱、炎症性疾病、疼痛、类风湿等症状是有用的。